Synamics Therapeutics, AI-Driven Drug Discovery Startup, Attracts Former Novozymes Executives as Lead Investors

Funding Rounds

▤ Summary

Synamics Therapeutics secured a lead investment in its pre-seed round from former Novozymes executives Steen Riisgaard and Per Falholt. The Copenhagen-based startup uses AI to discover therapies aimed at overcoming drug resistance in cancer. The company will use the funding to validate its Dynaptive drug design platform. The investors bring deep biotechnology experience and signal external confidence in the company’s approach.

$ Funding

$
Amount - Total raised
□
Date July 10, 2024 Announcement date
◎
Investors Novozymes Lead investors
▥
Company http://www.synamics.com Funded company

▥ Classifications

industries
No industries detected
applications
No applications detected

◇ AskAI Classifications

Labels
No AI classifications detected

▦ Linked Companies